pyrazines has been researched along with Obesity in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (22.58) | 18.2507 |
| 2000's | 14 (22.58) | 29.6817 |
| 2010's | 31 (50.00) | 24.3611 |
| 2020's | 3 (4.84) | 2.80 |
| Authors | Studies |
|---|---|
| Hjelholt, AJ; Jessen, N; Jørgensen, JOL; Møller, N; Pedersen, SB; Søndergaard, E | 1 |
| Baggett, MV; Rhee, EP; Shepard, JO; Sise, ME; Stevens, JS | 1 |
| Alexopoulos, SJ; Beretta, M; Brandon, AE; Byrne, FL; Carrive, P; Chen, SY; Cooney, GJ; Garcia, CJ; Hargett, SR; Hoehn, KL; Lackner, C; Lawrence, RT; Lee, B; Olzomer, EM; Philp, A; Philp, AM; Salamoun, JM; Santos, WL; Shah, DP; Sligar, J; Tucker, SP; Turner, N | 1 |
| Abraham, NG; Boumaza, I; Faroqui, M; Peterson, SJ; Raza, A; Rubinstein, R; Stec, D; Zhang, Y | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 2 |
| Defronzo, RA; Dubé, JJ; Espinoza, S; Liang, H; Mohan, S; Musi, N; Shanmugasundaram, K; Sriwijitkamol, A; Tantiwong, P | 1 |
| Akaslan, SB; Arslan, M; Cakir, N; Degertekin, CK; Toruner, FB; Yilmaz, G | 1 |
| Chiba, S; Gotoh, K; Kakuma, T; Masaki, T; Mitsutomi, K; Shimasaki, T; Ueno, D; Yoshimatsu, H | 1 |
| Al-Shurbaji, A; Denison, H; Eriksson, JW; Himmelmann, A; Knutsson, M; Löfgren, L; Mårtensson, G; Nilsson, C; Tornqvist, H | 1 |
| Hayes, MR; McGrath, LE; Mietlicki-Baase, EG; Montaubin, O; Olivos, DR; Turner, CA | 1 |
| Abdul-Ghani, M; Clarke, GD; Daniele, G; DeFronzo, RA; Eldor, R; Merovci, A; Taranova, A; Tripathy, D; Xiong, J | 1 |
| Friedman, TC; Ivey, R; Lee, D; Shin, CS; Sinha-Hikim, AP; Sinha-Hikim, I | 1 |
| Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z | 1 |
| Gao, Y; Hao, S; Sun, J; Sun, X; Tian, X; Zhang, Z | 1 |
| Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T | 1 |
| Coen, PM; Goodpaster, BH | 1 |
| Al-Barazanji, K; Benson, W; Binz, J; Chen, L; Generaux, C; McNulty, J; Young, A | 1 |
| Braun, LR; De Sousa-Coelho, AL; Feldpausch, MN; Frontera, WR; Grinspoon, SK; Lee, H; Looby, SE; Makimura, H; Patti, ME; Stanley, TL; Suresh, C; Syu, S; Torriani, M | 1 |
| Altherr, EB; Fletcher, PJ; Higgins, GA; MacMillan, C; Pratt, WE; Silenieks, LB | 1 |
| Cognard, E; Shepherd, PR; Smith, GC; Vickers, MH | 1 |
| Boström, J; Cheng, L; Greasley, PJ; Hjorth, S; Nordberg, H; Olsson, RI; Ryberg, E; Tholander, J | 1 |
| Bilkovski, R; Faust, M; Freude, S; Krone, W; Laudes, M; Oberhauser, F; Schilbach, K; Schulte, DM; Schulz, O | 1 |
| Aguila, MB; Cardoso-de-Lemos, FS; de Carvalho, L; Gregório, BM; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Cattaneo, A; Cavagnini, F; Fatti, LM; Filippini, B; Grasso, A; Moro, M; Orsini, F; Pecori Giraldi, F; Scacchi, M | 1 |
| Kuritzky, L | 1 |
| Chiang, Y; Fantus, IG; Foltz, W; Jin, T; Ling, W; Shao, W; Yu, Z; Zhang, Z | 1 |
| Baggio, LL; Drucker, DJ; Grynpas, MD; Kyle, KA; Willett, TL | 1 |
| Aguila, MB; da Silva Faria, T; Gregório, BM; Mandarim-de-Lacerda, CA; Relvas-Lucas, B; Souza-Mello, V | 1 |
| Cho, JH; Ham, DS; Kim, ES; Kim, JW; Park, HS; Sun, C; Yeom, JA; Yoon, KH | 1 |
| de Lemos, ET; Fernandes, R; Mascarenhas-Melo, F; Mega, C; Oliveira, J; Reis, F; Teixeira, F; Vala, H | 1 |
| Boddu, ND; Cheskin, LJ; Kahan, S; Kumar, AA; Palamaner Subash Shantha, G; Samson, RJ | 1 |
| Guo, ZK; Lu, YL; Wu, H; Zhai, HL; Zhou, DQ | 1 |
| Gahler, RJ; Grover, GJ; Juneja, P; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
| Bjerve, KS; Grill, VE; Mostad, IL; Qvigstad, E | 1 |
| Alvarez-Castro, P; Casanueva, FF; Cordido, F; Dieguez, C; Isidro, ML | 1 |
| Buijs, MM; Frölich, M; Kok, P; Kok, SW; Meinders, AE; Pijl, H; Roelfsema, F; Van Ierssel, IH; Voshol, PJ | 1 |
| Ackermans, MT; Allick, G; Bisschop, PH; Endert, E; Meijer, AJ; Romijn, JA; Sauerwein, HP; Sprangers, F; Weverling, GJ | 1 |
| Buijs, MM; Frölich, M; Kok, P; Kok, SW; Meinders, AE; Pijl, H; Roelfsema, F; Stokkel, MP; Westenberg, JJ | 1 |
| Barrett, JE; Dunlop, J; Harrison, BL; Mazandarani, H; Rosenzweig-Lipson, S; Sabalski, J; Sabb, A; Stack, G; Welmaker, G; Zhang, J | 1 |
| Bergman, A; Blum, R; Chen, L; Dilzer, S; Herman, GA; Hilliard, D; Lasseter, K; Liu, F; Meehan, AG; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Wagner, JA; Wang, AQ; Zeng, W | 1 |
| Aubrecht, J; Cheung, JR; Chiang, P; Coelho, RV; Coffing, SL; Dalvie, DK; Kalgutkar, AS; Lame, ME; Maurer, TS; McClure, KF; Schildknegt, K; Smith, EB; Soliman, VF; Vage, C | 1 |
| Beers, DS; Brodbeck, RM; Chenard, BL; Guo, Q; Hammer, J; Hutchison, AJ; Kershaw, M; Krause, JE; Mao, J; Maynard, GD; Near, KE; Wustrow, DJ; Yuan, J; Zhao, H; Zhou, D | 1 |
| Cho, JH; Huh, KB; Kim, KR; Lee, EJ; Lee, HC; Lim, SK; Nam, MS; Nam, SY; Song, YD | 1 |
| Andreotti, AC; Caumo, A; Lanzi, R; Manzoni, MF; Moreschi, A; Pontiroli, AE | 1 |
| Boffano, GM; Camanni, F; Ghigo, E; Grottoli, S; Maccario, M; Oleandri, SE; Procopio, M; Taliano, M | 1 |
| Cho, JH; Huh, KB; Kim, KR; Lee, HC; Nam, MS; Nam, SY | 1 |
| Alvarez, CV; Casanueva, FF; Cordido, F; Dieguez, C; Peino, R; Peñalva, A | 1 |
| Groop, L; Saloranta, C | 1 |
| Lanzi, R; Malighetti, ME; Manzoni, MF; Pontiroli, AE | 1 |
| Casanueva, FF; Considine, RV; Cordido, F; Dieguez, C; Fernández Alvarez, J; Peinò, R; Peñalva, A; Rodriguez-Garcia, J; Rodriguez-Segade, S | 1 |
| Casanueva, FF; Cordido, F; Dieguez, C; Fernandez, T; Martinez, T; Peinó, R; Peñalva, A | 1 |
| Marks, V; Morgan, L; Norris, F; Ranganath, L; Wright, J | 2 |
| Boden, G; Rocha, DM; Santomauro, AT; Santos, RF; Silva, ME; Strassmann, PG; Ursich, MJ; Wajchenberg, BL | 1 |
| Andreotti, AC; Caumo, A; Lanzi, R; Luzi, L; Malighetti, ME; Manzoni, MF; Pontiroli, AE; Sereni, LP | 1 |
| Bolscher, E; Casanueva, FF; de Vries, WR; Dieguez, C; Koppeschaar, HP; Niesink, M; Smid, HE; Van Dam, PS; Waasdorp, EJ | 1 |
| Blachère, JC; Bukowiecki, LJ; Pérusse, F | 1 |
| Belosi, C; Cento, RM; Ciampelli, M; Lanzone, A; Leoni, F; Muzj, G; Romualdi, D | 1 |
| Apa, R; Ciampelli, M; Guido, M; Lanzone, A; Lattanzi, F; Leoni, F | 1 |
| Agius, L; Alberti, KG; Catalano, C; Fulcher, GR; Walker, M | 1 |
2 review(s) available for pyrazines and Obesity
| Article | Year |
|---|---|
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Interactions between glucose and FFA metabolism in man.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipolysis; Models, Biological; Niacin; Obesity; Pyrazines | 1996 |
21 trial(s) available for pyrazines and Obesity
| Article | Year |
|---|---|
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Topics: Acetates; Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Diarrhea; Dose-Response Relationship, Drug; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Intestinal Absorption; Male; Middle Aged; Obesity; Peptide YY; Pyrazines; Treatment Outcome; Weight Loss | 2014 |
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2013 |
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Topics: Adult; Blood Glucose; Body Composition; Down-Regulation; Energy Metabolism; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Obesity; Pyrazines; Young Adult | 2016 |
Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
Topics: Adult; Body Mass Index; Evaluation Studies as Topic; Female; Glucose Tolerance Test; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin; Male; Middle Aged; Obesity; Oligopeptides; Pyrazines | 2003 |
Acipimox enhances spontaneous growth hormone secretion in obese women.
Topics: Adipose Tissue; Adult; Body Composition; Entropy; Fatty Acids, Nonesterified; Female; Half-Life; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin-Like Growth Factor I; Obesity; Pyrazines | 2004 |
Free fatty acids increase hepatic glycogen content in obese males.
Topics: Adult; C-Peptide; Fasting; Fatty Acids, Nonesterified; Gas Chromatography-Mass Spectrometry; Gluconeogenesis; Glucose; Hormones; Humans; Hypolipidemic Agents; Insulin; Liver Glycogen; Male; Middle Aged; Obesity; Pyrazines; Stimulation, Chemical | 2004 |
Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment.
Topics: Adrenocorticotropic Hormone; Adult; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Down-Regulation; Fatty Acids, Nonesterified; Female; Follicular Phase; Humans; Hydrocortisone; Hypolipidemic Agents; Hypothalamo-Hypophyseal System; Obesity; Pituitary-Adrenal System; Premenopause; Pyrazines; Reference Values; Statistics, Nonparametric | 2004 |
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Administration, Oral; Blood Glucose; Body Weight; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoproteins; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.
Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glycerol; Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin-Like Growth Factor I; Lipolysis; Male; Middle Aged; Obesity; Pulsatile Flow; Pyrazines | 1994 |
Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
Topics: Adult; Fatty Acids, Nonesterified; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Male; Obesity; Pyrazines | 1996 |
Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Topics: Adolescent; Adult; Fatty Acids, Nonesterified; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Oligopeptides; Pyrazines; Pyridostigmine Bromide | 1996 |
Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Topics: Adult; Aged; Aging; Blood Glucose; Cross-Over Studies; Fatty Acids, Nonesterified; Female; Gonadotropin-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Lipolysis; Male; Obesity; Pyrazines; Single-Blind Method | 1996 |
Acute changes in free-fatty acids (FFA) do not alter serum leptin levels.
Topics: Adult; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Heparin; Humans; Hypolipidemic Agents; Kinetics; Leptin; Male; Obesity; Placebos; Proteins; Pyrazines | 1998 |
Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Topics: Adult; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Male; Middle Aged; Obesity; Pyrazines | 1998 |
Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Topics: Adult; Basal Metabolism; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Obesity; Oxidation-Reduction; Pyrazines | 1999 |
Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Topics: Aged; Area Under Curve; Blood Glucose; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Hormones; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 1; Male; Obesity; Oligopeptides; Pyrazines | 2000 |
Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; C-Peptide; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Growth Hormone-Releasing Hormone; Hormones; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipids; Obesity; Polycystic Ovary Syndrome; Pyrazines | 2001 |
A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome.
Topics: Adult; Blood Glucose; C-Peptide; Female; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Insulin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; Pyrazines; Thinness; Time Factors; Triglycerides | 2002 |
Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glycerol; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Male; Middle Aged; Obesity; Pyrazines; Pyruvates; Triglycerides | 1992 |
39 other study(ies) available for pyrazines and Obesity
| Article | Year |
|---|---|
Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals.
Topics: Adipose Tissue; Adult; Aged; Angiopoietin-Like Protein 4; Cross-Over Studies; Fatty Acids; Fatty Acids, Nonesterified; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Lipoprotein Lipase; Male; Middle Aged; Obesity; Pyrazines; RNA, Messenger; Single-Blind Method; Up-Regulation; Young Adult | 2020 |
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Aged; Alanine; Amides; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Continuous Renal Replacement Therapy; Coronavirus Infections; COVID-19; Creatinine; Humans; Hypertension; Lung; Male; Obesity; Pandemics; Pneumonia, Viral; Pyrazines; Radiography, Thoracic; SARS-CoV-2 | 2020 |
Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice.
Topics: Adipose Tissue; Administration, Oral; Animals; Blood Glucose; Body Temperature; Body Weight; Diamines; Diet, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose Clamp Technique; Humans; Insulin Resistance; Liver; Male; Membrane Potential, Mitochondrial; Mice; Mitochondria; Obesity; Oxadiazoles; Oxidative Stress; Pyrazines | 2020 |
Positive Effects of Heme Oxygenase Upregulation on Adiposity and Vascular Dysfunction: Gene Targeting vs. Pharmacologic Therapy.
Topics: Adiposity; Animals; Cell Line; Endothelial Cells; Enzyme Activators; Gene Targeting; Genetic Therapy; Heme Oxygenase-1; Male; Mice, Inbred C57BL; Obesity; Pyrazines; Pyrroles; Up-Regulation; Vasodilation | 2019 |
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.
Topics: Administration, Oral; Adult; Case-Control Studies; Ceramides; Chemokine CCL2; Diabetes Mellitus, Type 2; Diglycerides; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypolipidemic Agents; I-kappa B Kinase; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Middle Aged; Muscle, Skeletal; Obesity; Pyrazines; Signal Transduction; Toll-Like Receptor 4 | 2013 |
Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
Topics: Alanine Transaminase; Animals; Blood Glucose; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Female; Insulin; Insulin Resistance; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Triglycerides | 2013 |
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Ion Channels; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Obesity; PPAR gamma; Pyrazines; Sitagliptin Phosphate; Triazoles; Uncoupling Protein 1 | 2013 |
Intraduodenal milk protein concentrate augments the glycemic and food intake suppressive effects of DPP-IV inhibition.
Topics: Animals; Blood Glucose; Dipeptidyl Peptidase 4; Eating; Glucagon-Like Peptide 1; Hypoglycemic Agents; Male; Milk Proteins; Obesity; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2014 |
Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Mitochondria; Obesity; Pyrazines; Reactive Oxygen Species | 2014 |
Nicotine in combination with a high-fat diet causes intramyocellular mitochondrial abnormalities in male mice.
Topics: Acetyl-CoA Carboxylase; Adipose Tissue; Animals; Body Weight; Diet, High-Fat; Fatty Acids, Nonesterified; Lipolysis; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Mitochondria; Muscle Fibers, Skeletal; Muscle, Skeletal; Nicotine; Obesity; Oxidative Stress; Pyrazines; Risk Factors; Smoking; Triglycerides | 2014 |
Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects.
Topics: Adult; Animals; Area Under Curve; Blood Glucose; C-Peptide; Diet; Drug Synergism; Drug Therapy, Combination; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Lansoprazole; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Improved mitochondrial function is linked with improved insulin sensitivity through reductions in FFA.
Topics: Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Insulin Resistance; Male; Mitochondria; Obesity; Pyrazines | 2014 |
Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
Topics: Animals; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Synergism; Eating; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxadiazoles; Proto-Oncogene Proteins c-fos; Pyrazines; Receptors, G-Protein-Coupled; Weight Loss | 2015 |
Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.
Topics: Animals; Benzazepines; Choice Behavior; Dose-Response Relationship, Drug; Feeding Behavior; Impulsive Behavior; Male; Obesity; Piperazines; Pyrazines; Rats; Reward; Serotonin 5-HT2 Receptor Agonists | 2016 |
Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Body Composition; Body Weight; Clozapine; Dibenzothiazepines; Dietary Fats; Disease Models, Animal; Eating; Exenatide; Food Preferences; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Peptides; Pyrazines; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Novel thioamide derivatives as neutral CB1 receptor antagonists.
Topics: Animals; Anti-Obesity Agents; Disease Models, Animal; Mice; Mice, Obese; Obesity; Pyrazines; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Thioamides | 2010 |
Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Lipopolysaccharide Receptors; Male; Membrane Proteins; Middle Aged; Monocytes; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Energy Intake; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2010 |
The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.
Topics: Adult; Aged; Arginine; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin; Insulin-Like Growth Factor I; Linear Models; Lipolysis; Male; Middle Aged; Obesity; Pyrazines | 2010 |
Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice.
Topics: Animals; Antioxidants; Blotting, Western; Dietary Fats; Hep G2 Cells; Humans; Insulin Resistance; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Obesity; Oxidative Stress; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Thiones; Thiophenes | 2011 |
Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Dipeptidyl Peptidase 4; Female; Hypoglycemic Agents; In Vitro Techniques; Male; Mice; Mice, Knockout; Obesity; Ovariectomy; Pioglitazone; PPAR gamma; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2011 |
Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Insulin; Islets of Langerhans; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Obesity; Pancreas; Pancreas, Exocrine; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2011 |
Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Fasting; Glucose Tolerance Test; Homeostasis; Insulin-Secreting Cells; Ki-67 Antigen; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Organ Size; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2011 |
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Insulin; Kidney Glomerulus; Lipid Peroxidation; Lipids; Male; Obesity; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Overweight; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Weight Loss | 2012 |
Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.
Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Liver; Male; Obesity; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2012 |
Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Obesity; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Satiation; Sitagliptin Phosphate; Triazoles | 2012 |
Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dietary Proteins; Energy Intake; Exercise; Fasting; Fatty Acids; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Proinsulin; Pyrazines | 2003 |
Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
Topics: Animals; Anti-Obesity Agents; Arachidonic Acid; Behavior, Animal; Binding Sites; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Eating; Humans; Male; Mice; Mice, Inbred C57BL; Obesity; Phosphoric Monoester Hydrolases; Pyrazines; Quinoxalines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Tritium | 2006 |
Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.
Topics: Biotransformation; Mutagenicity Tests; Obesity; Piperazines; Pyrazines; Salmonella typhimurium; Serotonin 5-HT2 Receptor Agonists | 2007 |
Aminopyrazine CB1 receptor inverse agonists.
Topics: Animals; Blood Glucose; Combinatorial Chemistry Techniques; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Feeding Behavior; Humans; Microsomes, Liver; Molecular Structure; Obesity; Piperidines; Pyrazines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship | 2008 |
Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
Topics: Adult; Cohort Studies; Drug Synergism; Fatty Acids, Nonesterified; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Kinetics; Male; Obesity; Pyrazines; Reference Values; Time Factors | 1995 |
Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
Topics: Adult; Arginine; Fatty Acids, Nonesterified; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Obesity; Pyrazines | 1996 |
Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.
Topics: Adult; Analysis of Variance; Area Under Curve; Case-Control Studies; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Tolerance Test; Heparin; Humans; Insulin; Models, Biological; Neurotransmitter Agents; Obesity; Peptide Fragments; Postprandial Period; Pyrazines; Triglycerides | 1999 |
The effect of circulating non-esterified fatty acids on the entero-insular axis.
Topics: Adult; Blood Glucose; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heparin; Humans; Insulin; Intestines; Islets of Langerhans; Obesity; Peptide Fragments; Protein Precursors; Pyrazines | 1999 |
Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
Topics: Adult; Body Mass Index; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hyperinsulinism; Hypolipidemic Agents; Insulin; Male; Obesity; Pyrazines | 1999 |
Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dioxoles; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Male; Obesity; Pyrazines; Rats; Rats, Zucker | 2001 |